⌕
Halozyme Therapeutics · HALO · Nasdaq
Tenet 71 · Solid
Compare
$95.97−0.55%At closeTenet 71 · Solid
$95.97−0.53 (−0.55%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Halozyme Therapeutics (HALO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~33.2%/yr (FY21→FY25), net margin 22.7%, and free cash flow (~$644.6M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲37.6%
1,396.6
FY21→FY25CAGR +33.2%/yr
Net income ($M)▼28.6%
316.9
one-off year: see footnoteCAGR −5.8%/yr
Free cash flow ($M)▲37.6%
644.6
FY21→FY25CAGR +21.3%/yr
Diluted EPS▼25.4%
2.56
buyback-liftedCAGR −1.7%/yr
What the receipts whisper · what a headline number hides
Share count
−15.6%

146.8mn → 123.9mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$7.0M

−34.8% YoY in FY25 · 0.5% of revenue.

Returns vs FCF
53%

$342.4M returned vs $644.6M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)1396.6Revenue−228.8COGS1167.8Gross profit−366.4R&D−207.1SG&A469.0Op income−152.1Tax & other316.9Net income

23¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 81.6% → 83.6%. Net margin 22.7% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,802.41,396.61,015.3829.3660.1443.3▲37.6%+33.2%
Cost of revenue
319.7228.8159.4192.4139.381.4▲43.5%+29.5%
Gross profit
1,482.81,167.8855.9636.9520.8361.9▲36.4%+34.0%
Research & development
397.8366.479.076.466.635.7▲363.5%+79.0%
Selling, general & admin
250.1207.1154.3149.2143.550.3▲34.2%+42.4%
Total operating expenses
808.5698.8304.4299.3253.386.0▲129.6%+68.8%
Operating incomefeeds ROC rank
674.2469.0551.5337.6267.5275.9▼15.0%+14.2%
Other income, net
−19.2−2.15.710.8−18.6−27.4——
Pretax income
655.0466.9557.1348.3248.9248.5▼16.2%+17.1%
Income tax
169.6150.0113.066.746.8−154.2▲32.7%+47.4% (22→25)
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
485.4316.9444.1281.6202.1402.7▼28.6%−5.8%
Per share
Diluted EPSbuyback-sensitive
4.002.563.432.101.442.74▼25.4%−1.7%
Diluted shares (mn)
122.61123.90129.42134.20140.61146.80▼4.3%−4.1%
Margins
Gross margin76th pct in Healthcare
82.3%83.6%84.3%76.8%78.9%81.6%▼0.7pp+2.0pp
Operating margin
37.4%33.6%54.3%40.7%40.5%62.2%▼20.7pp−28.7pp
Net margin92nd pct in Healthcare
26.9%22.7%43.7%34.0%30.6%90.8%▼21.0pp−68.2pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −62% vs a 19% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 32% vs a 19% norm for this window, likely a one-time item; see the filing.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Halozyme Therapeutics' revenue last fiscal year?

Halozyme Therapeutics reported revenue of $1,396.6M in fiscal 2025, up 37.6% from fiscal 2024.

What was Halozyme Therapeutics' net income?

Halozyme Therapeutics reported net income of $316.9M in fiscal 2025, a net margin of 22.7%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.